The team at Imperial College Healthcare NHS Trust (UK) randomised the first participant into the PRESTIGE-AF Study.

The team at Imperial College Healthcare NHS Trust (UK) have randomised the first participant into the PREvention of Stroke in Intracerebral
haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF) Study. 

Financed by the European Commission, PRESTIGE-AF is a 6.9 million Euro European collaborative research project aimed to reduce the risk of further stroke for intracerebral haemorrhage (ICH) survivors with atrial fibrillation (a heart condition that causes an irregular and often abnormally fast heart rate). PRESTIGE-AF has partner institutions from the UK, Germany, Austria, Spain, France, Italy, and Denmark.

Why is this project important? Stroke is one of the largest public health challenges around the world. It is the most common cause of adult-acquired disability, the second leading cause of death globally and the second most frequent cause of dementia. In addition, as stroke is a disease of the elderly, its impact is expected to further increase in the coming decades due to the ageing population.

At the core of the PRESTIGE-AF project is a clinical trial gathering evidence around recommended medication for stroke prevention in ICH patients with atrial fibrillation. Sub-studies will explore individual predictive risk modelling using brain imaging, genetic testing and other biological markers.

Other aspects of the project will include exploring cognitive and psychological factors and drug adherence in these patients.

For more information about the clinical trials:

Clinical Trial Delivery Manager
Kirsten Harvey
kirsten.harvey@imperial.ac.uk

To keep up to date with the PRESTIGE-AF Study, Follow us on Twitter @PRESTIGE_AF2020 and visit our website www.prestige-af.org.